Second-trimester maternal serum screening for fetal Down syndrome: As a screening test for hemoglobin Bart's disease: A prospective population-based study

2018 ◽  
Vol 38 (9) ◽  
pp. 700-705 ◽  
Author(s):  
Chanane Wanapirak ◽  
Wirawit Piyamomgkol ◽  
Supatra Sirichotiyakul ◽  
Fuanglada Tongprasert ◽  
Kasemsri Srisupundit ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Screening Test ◽  
Population Based ◽  
Maternal Serum ◽  
Second Trimester ◽  
Maternal Serum Screening ◽  
Population Based Study ◽  
Serum Screening

Second-trimester Down syndrome maternal serum screening in twin pregnancies: impact of chorionicity

2003 ◽  
Vol 23 (4) ◽  
pp. 331-335 ◽  
Author(s):  
Fran�oise Muller ◽  
Sophie Dreux ◽  
Henry Dupoizat ◽  
Serge Uzan ◽  
Marie-Fran�oise Dubin ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Maternal Serum ◽  
Second Trimester ◽  
Maternal Serum Screening ◽  
Serum Screening ◽  
Twin Pregnancies

The evolving national birth prevalence of Down syndrome in Taiwan. A study on the impact of second-trimester maternal serum screening

2005 ◽  
Vol 25 (8) ◽  
pp. 665-670 ◽  
Author(s):  
Hei-Jen Jou ◽  
Yih-Shing Kuo ◽  
Jenn-Jeih Hsu ◽  
Ming-Kwang Shyu ◽  
T'sang-T'ang Hsieh ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Maternal Serum ◽  
Second Trimester ◽  
Maternal Serum Screening ◽  
Birth Prevalence ◽  
Serum Screening ◽  
The Impact

Second-trimester maternal serum screening for Down syndrome in twin-to-twin transfusion syndrome

2009 ◽  
Vol 29 (8) ◽  
pp. 814-815 ◽  
Author(s):  
Nathalie Sermondade ◽  
Sophie Dreux ◽  
Jean-François Oury ◽  
Françoise Muller
Keyword(s):  
Down Syndrome ◽  
Maternal Serum ◽  
Second Trimester ◽  
Maternal Serum Screening ◽  
Serum Screening

Prenatal serum screening for Down syndrome and neural tube defects in the United States: Changes in utilization patterns from 2012 to 2020

2021 ◽  
pp. 096914132110316
Author(s):  
Nathalie Lepage ◽  
Philip Wyatt ◽  
Edward R Ashwood ◽  
Robert G Best ◽  
Thomas Long ◽  
...  
Keyword(s):  
United States ◽  
Down Syndrome ◽  
First Trimester ◽  
The United States ◽  
Maternal Serum ◽  
Second Trimester ◽  
Maternal Serum Screening ◽  
Cell Free Dna ◽  
Free Dna ◽  
Serum Screening

Objective To compile current usage of serum-based prenatal screening for Down syndrome in the United States and compare it with results from a similar 2011/2012 survey. Setting The College of American Pathologists maternal screening proficiency testing survey includes a supplemental question on the first of three yearly distributions. Methods Information regarding tests offered and the monthly number of pregnancies tested for US-based laboratories were reviewed. Results were stratified by size of laboratory, tests offered, and pregnancies tested. Findings were compared to an earlier survey. Results Fifty-six laboratories reported they will have screened 1,131,336 pregnancies in 2020. Of these, 36% are screened by stand-alone first trimester testing, 48% by stand-alone second trimester testing, and 16% using tests that integrate results from both trimesters. Eighty percent of all serum screens were provided by the five laboratories that performed the most screens (at least 50,000). These five performed similar proportions of first or second trimester screens (42.2% and 41.8%, respectively). Compared to eight years earlier, there are now 54% fewer laboratories. Pregnancies screened using the first trimester, second trimester, and integrated protocols were lower by 27%, 69%, and 72%, respectively. The serum screening activity in the US showed a 62% decrease from 2012 levels. During 2012–2020, the number of cell-free DNA tests increased from negligible to 1,492,332. Conclusions Maternal serum screening for common aneuploidies has changed significantly in eight years with fewer laboratories, a shift toward larger laboratories and a 2.5-fold reduction in pregnancies tested, likely due to the introduction of cell-free DNA screening.

Sign in / Sign up

Export Citation Format

Share Document